![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2022
Krop, Ian E.; Im, Seock-Ah; Barrios, Carlos; Bonnefoi, Herve; Gralow, Julie; Toi, Masakazu; Ellis, Paul A.; Gianni, Luca; Swain, Sandra M.; Im, Young-Hyuck; De Laurentiis, Michelino; Nowecki, Zbigniew; Huang, Chiun-Sheng; Fehrenbacher, Louis; Ito, Yoshinori; Shah, Jigna; Boulet, Thomas; Liu, Haiying; Macharia, Harrison; Trask, Peter; Song, Chunyan; Winer, Eric P. und Harbeck, Nadia
(2022):
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
In: Journal of Clinical Oncology, Bd. 40, Nr. 5: S. 438-448
2019
Hurvitz, Sara A.; Martin, Miguel; Jung, Kyung Hae; Huang, Chiun-Sheng; Harbeck, Nadia; Valero, Vicente; Stroyakovskiy, Daniil; Wildiers, Hans; Campone, Mario; Boileau, Jean-Francois; Fasching, Peter A.; Afenjar, Karen; Spera, Gonzalo; Lopez-Valverde, Vanesa; Song, Chunyan; Trask, Peter; Boulet, Thomas; Sparano, Joseph A.; Symmans, W. Fraser; Thompson, Alastair M. und Slamon, Dennis
(2019):
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
In: Journal of Clinical Oncology, Bd. 37, Nr. 25